Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Barna Budai"'
Autor:
Bertalan Fekete, Lili Bársony, Krisztina Biró, Fruzsina Gyergyay, Lajos Géczi, Attila Patócs, Barna Budai
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background and Objective: Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) have co-morbidities treated with different drugs. The aim was to quantify the potential effect of co-medications on
Externí odkaz:
https://doaj.org/article/0c7bb170e213471d9f1633cf58e5907d
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Externí odkaz:
https://doaj.org/article/1dba3739fdfd4f558d3bfdc63a2c3e51
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Background: The literature data regarding colon cancer patients with liver-only metastases (CLM) show that NLR determined before metastasectomy is a prognostic marker of shorter relapse-free survival (RFS), but no results has been reported to date fo
Externí odkaz:
https://doaj.org/article/f8997d713a164e589099128b0af2f694
Publikováno v:
Magyar Onkologia; 2024, Vol. 68 Issue 3, p248-253, 6p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Márta Szőnyi, Erika Kovács, Krisztina Bíró, Dániel J. Erdélyi, László Noszek, Barna Budai, Lajos Géczi, Péter Prekopp
Publikováno v:
Journal of Molecular Medicine (Berlin, Germany)
Abstract Preventing the ototoxicity caused by cisplatin is a major issue yet to be overcome. Useful preventive treatments will soon be available. Consequently, the next step is to filter out those patients who are more prone to develop ototoxicity. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a85bb4b3619439f8a797da8ca6595c
https://doi.org/10.1007/s00109-020-01921-y
https://doi.org/10.1007/s00109-020-01921-y
Autor:
Barna Budai, László Landherr, Ágnes Ruzsa, Zsuzsanna Kahán, Tibor Csőszi, Károly Máhr, Zsolt Horváth, Katalin Boér, Gábor Rubovszky
Publikováno v:
Pathology and Oncology Research
Purpose: The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. The aim of this study was to determine the pCR rate obtained with dual HER2 blockade in routine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a39248c7841d1c99557905b1822de4
https://pubmed.ncbi.nlm.nih.gov/34257621
https://pubmed.ncbi.nlm.nih.gov/34257621
Autor:
Mihály Újhelyi, Norbert Mészáros, Balázs Madaras, Erna Ganofszky, Zoltán Mátrai, Gábor Rubovszky, Barna Budai, Tamás Pintér, Ákos Sávolt
In recent years some serologic parameters emerged as potential prognostic factors. The neutrophil-to-lymphocyte ratio (NLR) has the most evidence; however, other serologic factors were also reported. The only established systemic treatment in triple-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f691d11d863c029c7313abcf70ae7c26
https://doi.org/10.21203/rs.3.rs-144207/v1
https://doi.org/10.21203/rs.3.rs-144207/v1
Autor:
Tamás Martin, Edina Kiss, Barna Budai, Krisztián Nagyiványi, Lajos Géczi, Krisztina Bíró, Zsófia Küronya, Andrea Ladányi, Fruzsina Gyergyay, Mihály Szőnyi
Publikováno v:
Pathology Oncology Research
Real-world evidence from clinical practices is fundamental for understanding the efficacy and tolerability of medicinal products. Patients with renal cell cancer were studied to gain data not represented by analyses conducted on highly selected patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e746c17ba8b640b27040f2c5730a3c7
https://pubmed.ncbi.nlm.nih.gov/32572819
https://pubmed.ncbi.nlm.nih.gov/32572819
Autor:
Tamás, Martin, Magdolna, Dank, Krisztina, Biró, Zsófia, Küronya, Fruzsina, Gyergyay, Krisztián, Nagyiványi, Barna, Budai, Katinka, Fűrész, Lajos, Géczi
Publikováno v:
Magyar onkologia. 65(1)
Germ cell tumors of the testicle account for 1% of all tumors. Testicular cancer (TC) is the most common malignancy in men aged 15-35 years. Patients with TC have an excellent survival rate but often have not yet attempted to father children, and fer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::561fd292e27265fcef2dec0f19750d05
https://pubmed.ncbi.nlm.nih.gov/33730117
https://pubmed.ncbi.nlm.nih.gov/33730117